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Th   e ability to accurately monitor changes in joint meta-
bo lism  in vivo that may lead to and predict, at a much 
later date, onset of structural pathology detected by 
imaging is an important challenge for osteoarthritis (OA) 
biomarker research. A recent study has examined very 
early molecular biomarker changes in synovial ﬂ  uid (SF), 
sera and urine following anterior cruciate ligament 
rupture [1]. Th   is damage often leads, many years later, to 
the onset of OA. In animals, such an injury can result in 
OA onset within weeks [2]. As the joint is considered the 
focus of the pathology, it is important to determine 
whether analyses of more accessible body ﬂ  uids (urine 
and serum) reﬂ  ect biomarker changes in OA joints. SF, 
serum and urine samples were taken from 11 patients on 
two consecutive occasions approximately 15 and 47 days 
after rupture. Twenty-one diﬀ   erent biomarkers were 
analysed but seven were restricted to SF measures only. 
Previously, most biomarker studies – with some excep-
tions [3] – examined one or two biomarkers of special 
interest and availability, often in only one body ﬂ  uid. Th  e 
study of Catterall and colleagues is therefore helpful in 
that it sought to gain a broader picture of biomarker 
changes and their interrelationships between ﬂ  uids [1].
Th  e declines in SF proteoglycan glycosaminoglycan 
and aggrecan cleavage neoepitope contents contrasted 
with an increase in biomarkers of type I collagen degra-
dation, namely CTx1, NTx, C1,2C (the latter also detects 
type II collagen cleavage), and the cartilage type II 
collagen cleavage biomarker CTxII, now known to be 
mainly generated by type II cleavage in calciﬁ  ed cartilage 
[4]. But the authors’ claims that these proteoglycan and 
collagen changes reﬂ   ect what is seen in vitro when 
cartilage degradation is stimulated [1] are debateable, 
particularly since the most signiﬁ  cant collagen changes 
involved mainly type I collagen. One must also question 
the con  clusion that these biomarkers ‘demonstrated that 
there is signiﬁ  cant and measurable cartilage and bone 
damage after acute knee injury’. No such changes were 
shown clinically.
Some of the most interesting data in this paper come 
from asking whether biomarkers in body ﬂ  uids reﬂ  ect 
primarily joint-derived sources. Th  e much increased 
contents in SF over serum of aggrecan FA846, COMP 
and MMP3 point to a joint origin for these biomarkers. 
But there is only a correlation between serum and SF for 
MMP3, and then it is rather weak. It may therefore be 
better to look at these biomarkers in SF rather than in 
serum.
In contrast, the serum/urine bone biomarkers CTx1, 
NTx and osteocalcin show strong correlations with SF. 
None of these biomarkers are really elevated in SF 
(1.6-fold, 1.2-fold and 1.2-fold, respectively), however, 
suggest  ing that they arise primarily systemically, thereby 
explaining these correlations. If the biomarkers do arise 
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changes following joint injury, prior to onset of any 
recognisable pathology, we look forward to future 
larger biomarker studies of this kind in patients with 
clinically defi  ned arthritic changes to which we can 
relate biomarker data.
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changes in bone metabolism. Uninjured and nonarthritic 
controls are needed to help answer such questions.
An analysis of the interrelationships and possible 
correlations between bone, cartilage and inﬂ  ammation 
metabolism reﬂ  ected by biomarkers is invariably useful 
but was overlooked. Not only are the eﬀ  ects of inﬂ  am-
mation important to understand, but also whether bone 
changes accompany early changes in cartilages as 
suggested above. Analyses of data for ratios between 
biomarkers, such as those of matrix turnover/synthesis 
and degradation, were also lacking. Th  ese insights into 
the balance between synthesis and degradation can 
provide valuable additional information [5,6].
Earlier work by Kraus and colleagues pointed to the 
importance of relating measurements in SF to urea to 
correct for dilutions caused by joint eﬀ  usions [7]. Yet this 
correction was not applied by Catterall and colleagues. 
Are such corrections not necessary?
Th  e present discussion of this study by Catterall and 
colleagues [1] has provided important but sobering 
insights and reminders – we should exercise great 
caution in how we interpret biomarker data, and should 
endeavour to make sure we understand what the data 
mean. Until we have deﬁ   nitive indications that given 
changes in bio  markers in a given body ﬂ  uid do indeed 
consistently reﬂ  ect  speciﬁ   c clinical changes, we must 
avoid putting any reliance on biomarker data alone. We 
are still in an exploratory/assessment phase in our 
understanding of what molecular biomarkers can really 
oﬀ  er us. We have often seen that measurements in sera 
or urine may have no relationship to events measured in 
joints. Th  e study population was very small, asking too 
much of statistical analyses, and often only SFs were 
examined [1]. Studies were made of early events long 
before any degenerative structural changes would be 
expected, to which we could relate and make sense of the 
biomarker data. What we need are future clinical studies 
assessing head to head many diﬀ  erent biomarkers and 
diﬀ  erent  body  ﬂ   uids, as in this investigation. But in 
addition we must have structural joint changes in bone 
and cartilage to which we can relate.
Biomarker analyses alone are no longer the way to go. 
Th  ankfully the private/public OA initiative launched by 
the NIAMS/NIH and industry – now involving the 
expertise oﬀ  ered by the Osteoarthritis Research Society 
International – is one exercise that should provide us 
with momentum in better understanding biomarkers of 
diﬀ  erent kinds.
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